
    
      A 52-week multicenter, randomized, double-blind, parallel-group trial in 331 subjects with
      moderate to severe chronic plaque-type psoriasis of body weight 90 kg or higher at time of
      randomization.

      This study consisted of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks),
      treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).

      Subjects weree randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every
      2 weeks; Secukinumab 300 mg every 4 weeks.

      In addition, subjects from the 300 mg every 4 weeks group who do not achieve Psoriasis Area
      Severity Index (PASI) 90 response at Week 16 were randomized using a 1:1 ratio to either
      remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks
      starting at Week 16, until the end of treatment.
    
  